10/26/2009 | CV | Medarex tender offer for 2.25% convertibles expires; no notes tendered
|
9/24/2009 | CV | Medarex holders may put 2.25% convertibles following change of control
|
7/24/2009 | CV | Market Commentary: Intel eyed as volume name; Ingersoll-Rand, Actuant strong; Human Genome gains more; Medarex over par
|
12/11/2007 | CV | Market Commentary: WaMu resets price talk on preferreds; Countrywide, Fannie Mae, homebuilders hammered after rate cut
|
10/4/2006 | BTCVDD | Medarex receives consents to amend 2.25% convertibles
|
10/2/2006 | BTCVDD | Medarex amends solicitation for 2.25% convertibles, eliminates fee, adds call protection
|
9/22/2006 | BTCVDD | Medarex seeks consents to amend 2.25% convertibles after default notice
|
8/31/2006 | BTCVDD | Medarex receives default notice on 2.25% convertibles for failure to file 10-Q
|
1/14/2005 | CV | Medarex says all $147 million 4.25% notes converted ahead of redemption
|
12/15/2004 | CV | Medarex calls all $147 million 4.25% convertibles
|
12/7/2004 | CV | Market Commentary: CMS new deal bid at issue; Dress Barn bid up 3.5 points; Seacor launches overnighter
|
5/27/2004 | CV | Medarex to call 4.5% convertible subordinated notes
|
4/30/2004 | CV | Market Commentary: Conseco deal seen May 3 week after delay due to warning; price talk emerges on Genworth deal
|
4/28/2004 | CV | New Issue: Medarex upsized $150 million convertible yields 2.25%, up 30%
|
4/27/2004 | CV | Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
|
4/26/2004 | CV | Medarex to repurchase, redeem 4.5% convertibles
|
4/26/2004 | CV | Medarex $125 million convertible talked at 2.25-2.75%, up 25-30%
|
4/26/2004 | CV | Market Commentary: OSI Pharma skyrockets amid buying frenzy as stock shoots up 139%; 4 new deals emerge
|
7/22/2003 | CV | Medarex greenshoe exercised, raising convertibles to $125 million
|
7/18/2003 | CV | New Issue: Medarex sells $100 million convertible at 4.25%, up 27.5%
|
7/17/2003 | CV | Market Commentary: Market slides sharply, thanks to Nasdaq, but uptick in volatility gives some encouragement
|
7/17/2003 | CV | Medarex $100 million convertible talked to yield 3.75-4.25%, up 27.5-32.5%
|
7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|
2/4/2002 | CV | Market Commentary: Convertibles plunge as stocks dive, Solutia nixes new deal
|